

Index

Note: f and t refer to figures and tables, respectively

- A
 - Addiction
 - and breastfeeding 128
 - as described by American Society of Addiction Medicine 3
 - determinants of 3f
 - and exposure to adverse childhood events (ACE) 3
 - stigmatization of 58
 - American Pain Society 1
 - American Society of Addiction Medicine 3
 - Anxiety disorders
 - cognitive-behavioral therapy as first-line treatment for 31
 - gabapentin as treatment for 31–2
 - and labor and childbirth, as triggers 37
 - prevalence among with SUD 31
 - SSRI as treatment for 31
 - Attention Deficit Hyperactivity Disorder (ADHD)
 - in opioid-using pregnant women 30
 - pharmacologic medications for 30
 - B
 - Behavioral treatment
 - cognitive-behavioral therapy (CBT) 31
 - cognitive behavioral therapy for PTSD 38
 - factors to consider when evaluating pregnant women for OUD and other co-occurring mental health conditions 29f
 - psychotherapy for depression in pregnancy 30
 - psychotherapy for pregnant women with substance use disorder (SUD) 28
 - Bipolar Affective Disorder (BPAD)
 - and lithium use 31
 - mood stabilizers as treatment for 30
 - symptoms of 30
 - Breastfeeding
 - active addiction, risks to mother and infant 128
 - and alcohol use 128
 - and amphetamine use 128
 - and benzodiazepine use 128
 - by buprenorphine-maintained mothers 80
 - and codeine use 128
 - and dosing of buprenorphine, methadone 130
 - environment of, considerations for 133
 - and familiarization of lactation consultant with SUD 135
 - guidelines for the determination of breastfeeding candidacy for women with SUD 134f
 - guidelines for encouraging / discouraging breastfeeding in marijuana-using mothers 133
 - and health care provider attitudes 133
 - history of sexual abuse and inability to breastfeed 129
 - HIV as contraindication to breastfeeding 129
 - and inadequate care, premature discharge of women with SUD 132
 - lactation and anxiety 129
 - lactation challenges in mothers with substance use disorder (SUD) 127
 - lactation and active maternal addiction 128
 - lactation and maternal sexual trauma 129
 - lactation and maternal psychiatric illness 129
 - lactation and smoking 129
 - lactation consultant, use of 131
 - and lack of training of providers 132
 - and marijuana use 128
 - and maternal education 130
 - by methadone-stabilized mothers 80
 - medication considerations for 38
 - and modification of provider approach, environment 133
 - by mothers on methadone or buprenorphine, importance of 106
 - by mothers with hepatitis C, HIB 80
 - of infants with neonatal abstinence syndrome 130–1
 - and PCP use 128
 - percentage of women with opioid use disorder (OUD) who stop breastfeeding 106
 - pumping as red flag for sexual assault trauma 130
 - and psychiatric medication 130
 - and relapse prevention 128
 - trauma-informed care for women with SUD and sexual trauma 129
 - troubleshooting for women with SUD 68
 - by women on medication-assisted treatment (MAT) with methadone or buprenorphine 130
 - Brief intervention
 - guidelines for the determination of breastfeeding candidacy for women with SUD 134f
 - guidelines for encouraging / discouraging breastfeeding in marijuana-using mothers 133
 - and health care provider attitudes 133
 - history of sexual abuse and inability to breastfeed 129
 - HIV as contraindication to breastfeeding 129
 - and inadequate care, premature discharge of women with SUD 132
 - lactation and anxiety 129
 - lactation challenges in mothers with substance use disorder (SUD) 127
 - lactation and active maternal addiction 128
 - lactation and maternal sexual trauma 129
 - lactation and maternal psychiatric illness 129
 - lactation and smoking 129
 - lactation consultant, use of 131
 - and lack of training of providers 132
 - and marijuana use 128
 - and maternal education 130
 - by methadone-stabilized mothers 80
 - medication considerations for 38
 - and modification of provider approach, environment 133
 - by mothers on methadone or buprenorphine, importance of 106
 - by mothers with hepatitis C, HIB 80
 - of infants with neonatal abstinence syndrome 130–1
 - and PCP use 128
 - percentage of women with opioid use disorder (OUD) who stop breastfeeding 106
 - pumping as red flag for sexual assault trauma 130
 - and psychiatric medication 130
 - and relapse prevention 128
 - trauma-informed care for women with SUD and sexual trauma 129
 - troubleshooting for women with SUD 68
 - by women on medication-assisted treatment (MAT) with methadone or buprenorphine 130
 - brief interview (BI) and oral or written contract with patient 14
 - brief interview (BI), components of 14f
 - for low-risk groups 13
 - for moderate-risk group 13
 - and motivational interviewing (MI), purpose of 13
 - and objective of providers 13
 - referral to treatment of high-risk patients 14
 - and shaming, judgment 13
 - tasks of effective brief intervention 13
 - Buprenorphine. *See* individual entries under Medically supervised withdrawal (MSW), Opioid agonist treatment
- C
 - Child welfare
 - Child Abuse Prevention and Treatment Act (CAPTA), elements of 108
 - child welfare involvement and pregnancy outcomes 4
 - harmful legislation on 108
 - and opioid epidemic 77
 - state child-welfare statutes for classification of substance use during pregnancy 108
 - Chronic pain
 - in pregnant women 2
 - opioid use disorder (OUD) in pregnant women with chronic pain, and treatment decision-making 54
 - OUD in pregnant women with chronic pain, and detoxification 54
 - OUD in pregnant women with chronic pain, and taper of opioids 55
 - as risk factor for substance use disorder (SUD) 20
 - suggested components of care for opioid tapering 55f
 - Contraception
 - barriers to obtaining contraception for women with substance use disorder (SUD) 15
 - during postpartum period 107
 - lack of awareness of in women with SUD 107
 - Crack cocaine
 - crack-exposed children, legislation on 5

Index

- Criminalization of drug use during pregnancy
 fear of legal involvement and prevention
 of women from obtaining prenatal
 care 5
 and pregnant women of color, women in
 poverty 5
 state statutes for 5
- D
- Dementia
 and chronic use of neurotoxic substances
 such as alcohol, inhalants 31
 and substance use, withdrawal 31
 and medication taper 31
- Diagnostic and Statistical Manual of Mental
 Disorders (DSM)* 28
- Diagnostic Service Manual (DSM) 24
 criteria for diagnosing substance use
 disorder (SUD) 24
 DSM5 Criteria for Opioid Use Disorders 24f
- Domestic violence. *See* Intimate partner
 violence (IPV)
- E
- Eating disorders in pregnant women
 and adverse outcomes for mother and
 baby 32
 management of 32
 and substance use disorders (SUDs) 32
- F
- Ferguson v. City of Charleston* 22
- G
- General Educational Equivalent (GED)
 examination 69
- H
- Harm reduction. *See also* Opioid use
 disorder (OUD) in pregnant women,
 harm reduction principles of
 harm reduction, definition of 57
 harm reduction movement, history of 57
 as response to War on Drugs 58
 syringe exchange program, as harm
 reduction strategy 58
- I
- Incarceration
 of buprenorphine-treated women
 discharged from hospital 90
 of pregnant women with substance use
 disorder (SUD) 5
 in social care for pregnant women with
 SUD 68
- Intimate partner violence (IPV)
 co-occurring issues linked to IPV 42f
 context bonding perpetrators and victims
 of IPV 43–4
 critical harms of 43
 definition of 41
 examples of reasons keeping IPV Victim
 in relationship with perpetrator 43f
 guidelines for treatment of women with
 substance use disorder (SUD) during
 pregnancy 56
 interconnection between IPV and other
 life stressors 42
- IPV incidents of pregnant women with
 SUD vs. pregnant women without
 SUD 41
 and lack of education among
 professionals 45
 lifetime prevalence of IPV of women in
 the United States 42f
 morbidity of 43
 and pregnant women with SUD 41
 pregnancy as complicating factor in IPV
 43
 prevalence of SUD in IPV incidents 41
 provider steps for treating IPV in
 pregnant women with SUD 46
 risk factors for 41–2
 screening and assessing for IPV risk 44–5
 suggested components of IPV screening
 program 44
 treating IPV in pregnant women with
 SUD 45
 and unexpected pregnancy causing
 escalation of violence 43
 victims of IPV and likelihood to
 use substances before and during
 pregnancy 42
- Insomnia
 and benzodiazepine treatment, dangers
 of 31
 treatment with antihistamines,
 prescription sleep aids 31
- Intrauterine growth restriction (IUGR)
 and premature labor, risk of in women
 with opioid use disorder (OUD) who
 smoke 65
- L
- Labor and delivery
 admission and intrapartum management
 of women with substance use disorder
 (SUD) 96–7
 approach to labor and delivery for patient
 with unknown intoxicants 95–6
 and benzodiazepine misuse 95
 and cocaine / methamphetamine use 95
 fetal assessment, monitoring in setting of
 intoxication / withdrawal 96
 fetal heart rate in methadone-maintained
 patient at the time of admission;
 following administration of
 nalbuphine 10 mg IV; fetal tachycardia
 occurs; patient was symptomatic
 with severe withdrawal symptoms;
 following morphine IV with recovery
 of fetal heart rate to a normal baseline
 and normal variability 100f
 intrapartum care for patient with
 opioid use disorder (OUD),
 recommendations for 97
 and medication-assisted treatment
 (MAT) with methadone,
 buprenorphine 97
 and noncompliance with prenatal care,
 recommendations for patient in MAT
 program 97
 and opioid and alcohol intoxication as
 risk for reduced fetal heart rate 96
 and opioid-induced hyperalgesia
 (OIH) 98
- by patients with opioid use disorder
 not currently in treatment (OUD),
 recommendations for 97–8
 and substance use and smoking as risk for
 fetal growth restriction 96
 and treatment for opioid intoxication /
 withdrawal 95
 urine drug testing during 96
 urine drug testing, refusal of during labor
 and delivery 96
 by women with opioid use disorder
 (OUD) 96
- Labor and delivery, pain control during
 algorithm for intrapartum, postpartum
 pain control in women with opioid use
 disorder treated with methadone or
 buprenorphine 103f
 and avoidance of discontinuation of
 buprenorphine for women with
 opioid tolerance following caesarean
 delivery 102
 and breastfeeding, compatibility with
 methadone and buprenorphine 102
 buprenorphine and inability to
 control pain in women with opioid
 tolerance 101
 caesarean delivery, perioperative
 medications for 100–1
 and fear of relapse in women with
 substance use disorder (SUD) 102
 increased sensitivity to pain in patients
 with opioid use disorder (OUD) 98
 and intrapartum, postpartum pain
 control for patient with chronic opioid
 exposure 98
 MOTHER study on postoperative opioid
 use in women treated with methadone
 vs. buprenorphine 102
 neuraxial analgesia method of pain relief
 for labor and delivery 99–100
 and newborn considerations 102
 nitrous oxide 99
 non-pharmacologic interventions 98–9
 and opioid storage, lack of caution in for
 women with OUD 102
 pain scores and oxycodone use in
 women treated with methadone or
 buprenorphine following cesarean
 delivery 101f
 parenteral opioid treatment 99
 postpartum pain control for vaginal
 birth by women on methadone,
 buprenorphine 101
 opioid use following vaginal birth 101
 treatment of acute pain in opioid-tolerant
 patient following caesarean delivery 101
- Lactation. *See* entries under Breastfeeding
- M
- Major depressive disorder (MDD). *See also*
 Postpartum depression
 and pregnant women with OUD who
 were maintained on methadone, poor
 outcomes of 30
 symptoms of 30
 Medication use during pregnancy
 antidepressants for pregnant women 30
 diagnosis-specific management of 29

- general factors to consider when forming a medication treatment plan for a pregnant woman with OUD, and their potential effects on the health of the mother and fetus 29f
 - psychotropic medication, factors to consider 28
 - Maternal mortality
 - in United States, as leader of developed world 6
 - Medication-assisted treatment (MAT) 22. *See also* Opioid agonist treatment
 - and breastfeeding 130
 - in labor and delivery 96–7
 - with methadone, buprenorphine 97
 - opioid use disorder, MAT and increased risk of treatment discontinuation following delivery 105
 - Medically-supervised withdrawal (MSW)
 - buprenorphine, and hospital discharge for incarcerated women 90
 - buprenorphine, and risk of Neonatal abstinence syndrome (NAS) 88
 - buprenorphine as outpatient alternative to methadone 87
 - buprenorphine, induction of after fetal viability 88
 - buprenorphine, initiation and timing of 88
 - buprenorphine, lack of availability of 87
 - Clinical Opioid Withdrawal Scale (COWS) Worksheet for assessment of opioid withdrawal 89f
 - delivery system of medication during pregnancy in outpatient, inpatient settings 87
 - with long-term intensive behavioral treatment 21
 - obstetrical units for 88
 - in opioid agonist treatment (OAT) 21
 - risks of methadone vs. buprenorphine 88
- Mental health conditions in pregnant women. *See also* specific conditions
- American Psychiatric Association's *Diagnostic and Statistical Manual of Mental Disorders (DSM)*, s language for diagnosis of patients 28
 - co-occurring mental health conditions in pregnant women with opioid use disorder 27
 - incidence/epidemiology of mental health disorders in pregnant women 27
 - mental health conditions in pregnancy, definition of 27
 - and prenatal care 65
 - prevalence of mental health conditions in pregnant women with SUD vs. without 27
 - recommended approach for evaluation of pregnant woman with OUD or co-occurring mental health conditions 29
 - risk factors for increased rate of mental health conditions among pregnant and postpartum women 27
- Milagro Program 87
- MOTHER study on postoperative opioid use in women treated with methadone vs. buprenorphine 102
- N
- Nalaxone
 - and decrease of mortality from opioid overdose 60
 - for newborns with breathing problems 122
- Neonatal abstinence syndrome (NAS)
 - and agonist treatment for opioid use disorders (OUD) 116
 - assessment of with toxicology screening of meconium 118
 - assessment of using scoring system 118–20
 - autonomic nervous system signs of 118
 - and benzodiazepines, use of 115
 - breastfeeding as factor in decreasing NAS scores, need for treatment 120
 - and buprenorphine dose 116
 - and care setting 120
 - and crying as sign of 118
 - definition and signs of 80–1
 - diagnosis of, inconsistency in 114
 - factors related to 115
 - Finnegan Neonatal Abstinence Score as guideline of American Academy of Pediatrics 119
 - and gastrointestinal distress 117
 - gender of infant as factor of 116
 - genetic studies on 116
 - incidence of based of percentage of infants prenatally exposed to opioids 114
 - incidence of neonatal abstinence syndrome per 1,000 hospital births in the United States, 2009–2012 2f
 - and methadone dose 116
 - and methadone use vs. buprenorphine use 117
 - morbidity of infants exposed to opioid in utero, lack of data on 114–15
 - MOTHER study on 115
 - nonpharmacological interventions for 98–9
 - onset of 117–18
 - and respiratory distress 117
 - Finnegan Neonatal Abstinence Score 119f
 - seizures from 117
 - signs of 117
 - and smoking 115
 - and SSRIs, use of 115
 - standardizing treatment protocols for 120
 - treatment of 2
 - treatment protocol, lack of 81
 - Vermont Oxford Network, and standards of rooming-in setting 120
- Neonatal abstinence syndrome (NAS), treatment of
 - average recovery time of infant 121
 - with buprenorphine 121
 - with clonidine 122
- Cochrane Controlled Trials Register study 121
- medications used in 121
- morphine and methadone as treatment of choice 121
- morphine vs. phenobarbital 121
- nalaxone for newborns with breathing problems 122
- pharmacological treatment 120–3
 - with phenobarbital 121
 - with opioids vs. sedatives 121–2
 - and outcome of infants 123
 - recommendations by American Academy of Pediatrics 121
 - sample hospital management plan for neonates with NAS 122f
- Nitrous oxide 99
- O
- Opioid agonist treatment
 - and baseline EKG, need for 90
 - breastfeeding by buprenorphine-maintained mothers 80
 - breastfeeding by methadone-stabilized mothers 80
 - breastfeeding by mothers with opioid use disorder (OUD), guidelines for 80
 - buprenorphine and methadone delivery settings 85
 - buprenorphine, transfer to from methadone 85–6
 - history of during pregnancy 84–5
 - in labor, delivery and the postpartum period, recommendations for 80
 - legal mandates for methadone treatment during pregnancy 85
 - and medically-supervised withdrawal (MSW) 21
 - medication management in the postpartum period 80
 - methadone and buprenorphine, considerations for use in pregnancy 79t
 - methadone, dosage of 90
 - methadone dose adjustment for pregnant women, need for 90
 - methadone, initiation of 90
 - methadone treatment, principles of 77
 - methadone treatment, research on 77
 - methadone vs. buprenorphine 78–80
 - naltrexone 86
 - and neonatal abstinence syndrome (NAS) 85–6
 - opioid agonist pharmacotherapy 77–80
 - treatment objectives of 76
- Opioid clinics
 - and abuse epidemic, role in 1
- Opioid epidemic
 - and child welfare 108
 - history of 1–2
 - and maternal mortality rate, increase of in United states 105
- Opioids
 - overprescription of 19
 - rates of opioid pain reliever (OPR) overdose deaths, OPR treatment admissions, and kilograms of OPR sold in United States, 1999–2010 1f
 - and white middle class patients 1
 - and white women of childbearing age 1
- Opioid treatment
 - Centers for Disease Control and Prevention (CDC) guidelines for safe treatment 2

Index

- Opioid use disorder (OUD) in pregnant women. *See also* Substance use disorder (SUD)
genetic vulnerability for OUD 3
insurance coverage for adjunctive therapies, lack of 3
non-medication treatment of pain in pregnant women 2
physical signs of 20–1
and polysubstance use 21
and taking non-prescribed medications 19
treatment of 2
vulnerability of women for OUD, factors for 3
withdrawal symptoms of 21
- Opioid use disorder (OUD) in pregnant women, diagnosis and investigation of addiction severity index 73
in context of substance use among pregnant and non-pregnant women 72
with medical history 74
National Study of Drug Use and Health Data for Women 73f
required information in assessment of 72–3
- Opioid use disorder (OUD) in pregnant women, harm reduction of
and barriers to services, strategies for lowering of 58–9
harm reduction, definition of 57
harm reduction programs for pregnant women with OUD 59
harm reduction services for pregnant women with OUD 58
harm reduction services, key characteristics of 57
peer services, as treatment for pregnant women with SUD 59
syringe exchange programs for pregnant women with OUD 59
- Opioid use disorder (OUD) in pregnant women, medical care for
additional medical complications associated with opiate use disorder 50f
infectious disease diagnosis and treatment 50
medical history 49
physical exam 49–50
substance use history 49
- Opioid use disorder (OUD) in pregnant women, screening for
criteria for screening tests 22
ethical considerations in toxicology testing 22
and informed consent 22
toxicology and biomarkers as assessment tools 22–3
- Overdose
nalaxone treatment and decrease of mortality from opioid overdose 60
opioid overdose death rates among women 1
and relapse during postpartum period as risk for overdose death 105
- Oxycontin
vs. black tar heroin 2
and heroin as replacement for 2
and opioid use disorder (OUD) 1
release of in 1996 1
- P
- Pain Clinics. *See* opioid clinics
- Parenting by women with substance use disorder (SUD). *See also* Child welfare
challenges of for women with SUD 108
limited knowledge of by women with SUD 108
and stigmatization 108
- Pejorative language
and dehumanization of pregnant patients with substance use disorder (SUD) 6
in description of substance use disease 6
- Postpartum depression (PPD) in women with substance use disorder (SUD)
Edinburgh Postnatal Depression Scale as self-screening method for women with opioid use disorder (OUD) 107
rate of in women with OUD 107
risk factors for women with OUD 107
vulnerability for 107
- Prenatal care for women with substance use disorder (SUD)
and abortion reduction rate for women with SUD 65
birth plan, benefits of 67
care coordination for pregnant women with SUD 63–4
and dental care 66
drug testing, controversiality of 66
early prenatal care, importance of for women with SUD 64
early ultrasonographic examinations, reasons for 66
in final month of pregnancy 68
harm reduction strategies for 65
and high rates of urgent care and emergency service visits 66
and improved outcomes for women with SUD 63
initial physical examination, special considerations for 65
and late or missed appointment in women with SUD 66
mental health assessment, importance of 66
monitoring abstinence in women with SUD 21
patient-centered model of care for pregnant women with SUD 64
and planning of infant care 67
and planning of postpartum contraception 68
and postpartum pain management, planning for 67
and reducing substance use 65
review of patient medications 64
routine prenatal care for women with SUD 21
and routing screening, repeat STI testing, routine ultrasonographic examinations 67
- sample birth plan of pain management 67f
smoking cessation programs, use of 65
smoking as risk for intrauterine growth restriction (IUGR) 65
social services, role of 65
third trimester care 67
treatment of mental health disorders 21
- Postpartum care for women with substance use disorder (SUD)
and breastfeeding, addressing challenges of 68
and breastfeeding for mothers on methadone or buprenorphine
importance of 106
increased dosage of opioids needed for women with opioid use disorder (OUD) vs. women without OUD 106
and increased pain after caesarean delivery 106
methadone, discontinuation rate of women with OUD 105
and maternal mortality rate, increase of in United States due to opioid epidemic 105
and maternal mortality rate of women with OUD 105
National Survey on Drug Use and Health, relapse rate for alcohol, cannabis in postpartum period 105
non-pharmacological interventions 106
opioid use disorder, medicated-assisted treatment (MAT) and increased risk of treatment discontinuation following delivery 105
peer support groups 107
and quitting smoking, percentage of 105
and reducing risk of unplanned pregnancy with contraception 106
and relapse as risk for overdose death 105
and resumption of substance use, treatment discontinuation, reasons for 106
and risk of relapse 105
short-acting opioids with maintenance doses of buprenorphine, methadone 106
social, environmental stressors for women with SUD 107
- Postpartum period
post-traumatic stress syndrome (PTSD) during 35
and relapse, risk of for women with substance use disorder (SUD) 15, 105
- Post-traumatic stress disorder (PTSD)
prevalence of PTSD in pregnant women with OUD 36
and contra-indications of benzodiazepine treatment 38–9
during postpartum period 36
and medical history of pregnant women, importance of 37
in pregnant women and risk for perinatal complications 36
in pregnant women with opioid disorder (OUD), case study on 35
prevalence of in pregnant women 35
PTSD in pregnant women and substance use, opportunities for research on 38

- sample cluster symptoms of PTSD in the perinatal period 36f
trauma and PTSD in women with OUD in pregnancy 35
Project Respect 87
- Q
Quinones, Sam 1
- R
Relapse
 during postpartum period 15
 fear of relapse in women with substance use disorder (SUD) following delivery 102
 and substance use during pregnancy 6
 as risk for overdose death during postpartum period 105
Remission 25
Risky drinking during pregnancy
 American Society of Addiction Medicine criteria (ASAM criteria) establishment of levels of care for 25
- S
SBIRT (screening, brief intervention, and referral to treatment)
 barriers to SBIRT Implementation in obstetric practice 15
 flow chart of SBIRT in practice 12f
 in rural counties, challenges of implementation 15
 SBIRT as public health approach to early intervention for SUD 9
 SBIRT research and lack of focus on illicit drugs compared to alcohol and tobacco 9
Schizophrenia
 prevalence of in pregnant women 32
 symptoms of 32
Seeking Safety model for substance use, PTSD in pregnant women 38
Sexually-transmitted diseases (STDs)
 hepatitis B 50–1
 hepatitis C (HCV) 51–2
 hepatitis C screening 52f
 human immunodeficiency virus (HIV) 52–4
 indications for repeat HIV testing in third trimester 53f
 in pregnant women with OUD, types of 50
Sheway pregnancy outreach program 60
Special needs services for pregnant women with substance use disorder (SUD) 59–60
Social care for pregnant women with substance use disorder (SUD)
 building systems of care 69–70
 Child Protective Services (CPS) intervention in 69
 court intervention in 69
 and housing instability 68
 and incarceration 68
 parole officers, role of 69
Stigmatization
 of addiction, impact on pregnant women with substance use disorder (SUD) 58
 as cause for non-disclosure and denial of substance use 19
 and parenting by women with SUD 108
 of pregnant women who use drugs 58
 and pregnant women with substance use disorders (SUD) 6
Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Treatment (CSAT) 4
Substance use disorder (SUD) in pregnant women. *See also* Opioid use disorder (OUD)
 and adverse life circumstances 15
 and chronic pain 20
 legal problems of 20
 national survey data on 9
 poor outcomes of 9
 risk factors for 20
 risk pyramid for substance use in pregnancy 12f
 substance use in women of childbearing age, percentage of 9
 and treatment of intimate person violence (IPV) trauma 45
Substance use disorder (SUD) in pregnant women, approaches to
 compelling women to get treatment through child welfare / criminal justice system 5–6
 incarceration of pregnant women 5
 mandating treatment, problems of 5
 model of comprehensive care of mothers with substance use disorders by Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Treatment (CSAT) 4
 public policy approaches 3
 and relapse 15, 102, 105, 127
 removal of children from mothers 21–3
Substance use disorder (SUD) in pregnant women, diagnosis and identification of criteria for diagnosis in Diagnostic Service Manual (DSM) 24
 examination of skin for needle marks, inflammation 20–1
 identifiable risk factors in non-identified women 19
 identification using state prescription monitoring programs (PMPs) 19
 management of identified and non-identified women 19
 PMP data sharing between states 19
 for pregnant women not identified with initial screening 19
 non-disclosure and denial of substance use 19
 out-of-state prescriptions, as barrier to identification 19
 remission, diagnostic description of 24–5
Substance use disorder (SUD) in pregnant women, screening for. *See also* SBIRT and biased reporting against racial and ethnic minorities 12
 components of screening, brief intervention, referral to treatment (SBIRT) 10f
 and conversation between provider, patient 11
 examples of screening instruments 11f
 and failure to disclose substance use 9
 flow chart of SBIRT in practice 13f
 interpretation of urine drug screens 24
 open-ended questions regarding use of tobacco, alcohol and other drugs 10
 perinatal provider, role of 9
 phosphatidyl ethanol (PEth) and hair analysis 27
 recommendations by professional organizations 10
 and risk factors 10
SBIRT (screening, brief intervention, and referral to treatment), as public health approach to early intervention for SUD 9
SBIRT research and lack of focus on illicit drugs compared to alcohol and tobacco 9
toxicology testing and ethical position of providers 11
toxicology testing, and unacknowledged risk factors 12
toxicology testing, limitations and negative consequences of 11
urine drug screening (UDS) 23
urine drug screening, considerations for 23
urine drug testing (UDT), and false positives, false negatives 12
urine drug testing, and follow-up by mass spectrometry testing (MS) 12
urine drug testing and metabolization of opioids 24
urine testing for heroin, codeine 24
urine toxicology testing 10
 and zones of risk given pattern of use 12
- T
Trauma. *See also* Post-traumatic stress disorder (PTSD) and Intimate partner violence (IPV)
 gynecologic exam and childbirth as trigger for PTSD 37
 models of trauma treatment programs 46
 opioid use disorder (OUD) and exposure to trauma, consequences of 36
 pregnant women with history of trauma and opioid use 35
 trauma-informed, definition of 45
 trauma-informed treatment for women with OUD 75–6
 trauma-specific care for pregnant women with substance use disorder, lack of 36
 trauma-specific services vs. trauma-informed services 46
- U
Unplanned pregnancy
 and contraception usage rate by women with substance use disorder 107
 rate of in women with SUD 64, 107
 reducing risk of in women during postpartum period 107